Follicular Lymphoma

From the Journals

PDPK1 could be novel target in MCL

The poor prognosis of mantle cell lymphoma despite advances in immunochemotherapy means that new therapeutic targets are needed.


Duvelisib NDA granted priority review

The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for duvelisib, a dual PI3K delta/gamma...